Tandem Diabetes Care Inc at Barclays Global Healthcare Conference Transcript
Well, it looks like Matt is not here yet. And so maybe what I can do is to start off by giving you kind of an update on how the business is doing. And if you guys have any questions, more than happy to field them right here. There he is.
I will start off by saying that last year was a challenging year for Tandem. We anticipated that we would see some challenges from COVID and from our competition but we didn't really anticipate that we would be -- the macroeconomic (inaudible) that was somewhat of a surprise to us. And if you go through the year, certainly in the back half of the year as the competition came to market, we did see our growth rate slow.
When you look at exactly how that happened, it was primarily from MDI conversions, people who are moving from pens and needles (inaudible). And I think that we finished the year, we actually grew 15%. And rather than try to just evaluate all of these factors and how they're going to affect us this coming year in 2023, we took a relatively conservative approach.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
